Evidence map›Paper›PMID 33608536›Full record

ArticleNature communications2021

Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic.

T R W Tipton, Y Hall, J A Bore, A White, L S Sibley, C Sarfas, Y Yuki, M Martin, S Longet, J Mellors and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

T R W TiptonNational Infection Service, Public Health England, Porton Down, Salisbury, UK. tom.tipton@phe.gov.uk.ORCID 0000-0002-0573-528X
Y HallNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
J A BoreCenter for Training and Research on Priority Diseases including Malaria in Guinea (CEFORPAG), Nongo, Conakry, Guinea.
A WhiteNational Infection Service, Public Health England, Porton Down, Salisbury, UK.ORCID 0000-0001-9481-0079
L S SibleyNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
C SarfasNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
Y YukiBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Frederick, MD, USA.
M MartinBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Frederick, MD, USA.
S LongetNational Infection Service, Public Health England, Porton Down, Salisbury, UK.ORCID 0000-0001-5026-431X
J MellorsNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
K EwerThe Jenner Institute, Oxford, UK.ORCID 0000-0001-9827-9836
S GüntherBernhard Nocht Institute for Tropical Medicine, Hamburg, DE, Germany.ORCID 0000-0002-6562-0230
M CarringtonBasic Science Program, Frederick National Laboratory for Cancer Research in the Laboratory of Integrative Cancer Immunology, National Cancer Institute, Frederick, MD, USA.ORCID 0000-0002-2692-2180
M K KondéCenter for Training and Research on Priority Diseases including Malaria in Guinea (CEFORPAG), Nongo, Conakry, Guinea.
M W CarrollNational Infection Service, Public Health England, Porton Down, Salisbury, UK.
Public Health England · GBFrederick National Laboratory for Cancer Research · USGerman Center for Infection Research · DEJenner Institute · GBRagon Institute of MGH, MIT and Harvard · US

Funding

Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001EWellcome TrustWellcome Trust 214626/Z/18/Z
6 · The paper itself

Abstract

Zaire ebolavirus (EBOV) is a highly pathogenic filovirus which can result in Ebola virus disease (EVD); a serious medical condition that presents as flu like symptoms but then often leads to more serious or fatal outcomes. The 2013-16 West Africa epidemic saw an unparalleled number of cases. Here we show characterisation and identification of T cell epitopes in surviving patients from Guinea to the EBOV glycoprotein. We perform interferon gamma (IFNγ) ELISpot using a glycoprotein peptide library to identify T cell epitopes and determine the CD4

Indexed as

Africa, WesternCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEbolavirusEnzyme-Linked Immunospot AssayEpidemicsEpitopes, T-LymphocyteGlycoproteinsHemorrhagic Fever, EbolaHumansImmunity, CellularInterferon-gammaSurvivorsT-LymphocytesEpitopes, T-LymphocyteGlycoproteinsInterferon-gamma

Identifiers

PMID33608536
PMCPMC7895930
OpenAlexW3129534606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.